ID29943A - Senyawa dds dan metode pengukurannya - Google Patents

Senyawa dds dan metode pengukurannya

Info

Publication number
ID29943A
ID29943A IDW00200101143A ID20011143A ID29943A ID 29943 A ID29943 A ID 29943A ID W00200101143 A IDW00200101143 A ID W00200101143A ID 20011143 A ID20011143 A ID 20011143A ID 29943 A ID29943 A ID 29943A
Authority
ID
Indonesia
Prior art keywords
measurement methods
dds
compound
compound dds
measurement
Prior art date
Application number
IDW00200101143A
Other languages
English (en)
Inventor
Hiroshi Susaki
Kazuhiro Inoue
Hiroshi Kuga
Masahiro Ikeda
Yoshinobu Shiose
Hiroshi Korenaga
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of ID29943A publication Critical patent/ID29943A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IDW00200101143A 1998-10-30 1999-10-29 Senyawa dds dan metode pengukurannya ID29943A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31013098 1998-10-30
JP32927298 1998-11-19

Publications (1)

Publication Number Publication Date
ID29943A true ID29943A (id) 2001-10-25

Family

ID=26566202

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101143A ID29943A (id) 1998-10-30 1999-10-29 Senyawa dds dan metode pengukurannya

Country Status (15)

Country Link
US (2) US6811996B1 (id)
EP (2) EP1619210A1 (id)
KR (1) KR20010090602A (id)
CN (2) CN1191093C (id)
AU (1) AU765409B2 (id)
BR (1) BR9915198A (id)
CA (1) CA2348931A1 (id)
EA (1) EA003790B1 (id)
HK (1) HK1042438A1 (id)
ID (1) ID29943A (id)
IL (1) IL142842A0 (id)
MX (1) MXPA01004239A (id)
NO (1) NO20012128L (id)
TW (1) TWI232930B (id)
WO (1) WO2000025825A1 (id)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
EA003398B1 (ru) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
CN1191093C (zh) * 1998-10-30 2005-03-02 第一制药株式会社 Dds化合物及其测定方法
US20030166513A1 (en) * 2000-06-29 2003-09-04 Akihiro Imura Dds compound and process for the preparation thereof
WO2005110430A1 (en) * 2004-05-10 2005-11-24 Michigan State University Method of use of carboxylated polysaccharides topically on the eyeball
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
CA2625426A1 (en) * 2005-09-22 2007-03-29 Hadasit Medical Research Services & Development Limited Dextran and arabinogalactan conjugates of therapeutically active compounds
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
TW201348244A (zh) * 2012-05-23 2013-12-01 Iner Aec Executive Yuan 醣質藥物造影劑前驅物之合成方法
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
CA2908993C (en) 2013-04-10 2023-05-23 Syndevrx, Inc. Metap2 inhibitors and methods of treating obesity
AU2014371934B2 (en) * 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
ES2893749T3 (es) 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
CA3239447A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
CA3011946A1 (en) * 2016-03-07 2017-09-14 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
SG11201901841TA (en) 2016-09-02 2019-03-28 Arrowhead Pharmaceuticals Inc Targeting ligands
KR20190066026A (ko) 2016-10-07 2019-06-12 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗gpr20抗体及び抗gpr20抗体−薬物コンジュゲート
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物及其用途
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体-薬物コンジュゲートの薬物部位を認識する蛋白質
CA3108044A1 (en) 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
JP2022512826A (ja) 2018-10-26 2022-02-07 シンデブルックス,インコーポレイティド MetAP2阻害剤のバイオマーカーとその応用
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
CN118047886A (zh) * 2022-11-17 2024-05-17 菲鹏生物股份有限公司 化合物及其制备方法和封闭剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
JP2791001B2 (ja) 1990-02-16 1998-08-27 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
JPH0784481B2 (ja) 1991-02-21 1995-09-13 株式会社デイ・デイ・エス研究所 カルボキシメチルマンノグルカン及びその誘導体
JP2589431B2 (ja) 1991-05-13 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリグルタミン酸誘導体及びその製造法
JP2774417B2 (ja) 1991-08-07 1998-07-09 株式会社ディ・ディ・エス研究所 ペプチド骨格を有する分枝鎖型糖複合体及び微粒子キャリヤー
JP2589435B2 (ja) 1991-09-17 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリリジン誘導体
JP2774429B2 (ja) 1992-03-17 1998-07-09 株式会社ディ・ディ・エス研究所 糖骨格を有する分枝鎖型誘導体
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
ES2149867T3 (es) * 1993-02-26 2000-11-16 Drug Delivery System Inst Ltd Derivados de polisacaridos y soportes para farmacos.
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
GB2282384B8 (en) * 1993-08-18 1997-09-04 Europ Economic Community Drug delivery agents incorporating mitomycin
JP3418693B2 (ja) 1993-09-06 2003-06-23 敏宏 赤池 ポリ−ε−置換−L−リジンのD−ガラクトピラノシル−グルコン酸誘導体
JPH07228688A (ja) 1994-02-18 1995-08-29 Yamanouchi Pharmaceut Co Ltd 糖修飾ポリ−ω−置換−L−グルタミン酸誘導体およびその製造方法
US5658592A (en) 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
JP3001381B2 (ja) 1994-09-16 2000-01-24 株式会社ディ・ディ・エス研究所 臓器移行性を有する多糖誘導体および薬物担体
US5886143A (en) * 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
JP3053764B2 (ja) 1995-03-17 2000-06-19 財団法人神奈川科学技術アカデミー 糖鎖高分子及びそれを用いた細胞処理剤並びに処理方法
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
JP2001505194A (ja) * 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
US6340461B1 (en) * 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
JP2002508758A (ja) * 1997-06-12 2002-03-19 エムエル・ラボラトリーズ・パブリック・リミテッド・カンパニー 生物的に活性な材料
EA003398B1 (ru) 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
CN1191093C (zh) * 1998-10-30 2005-03-02 第一制药株式会社 Dds化合物及其测定方法

Also Published As

Publication number Publication date
AU765409B2 (en) 2003-09-18
KR20010090602A (ko) 2001-10-18
NO20012128D0 (no) 2001-04-30
NO20012128L (no) 2001-06-20
CN1661044A (zh) 2005-08-31
EA003790B1 (ru) 2003-10-30
BR9915198A (pt) 2001-08-14
US6811996B1 (en) 2004-11-02
EP1619210A1 (en) 2006-01-25
CN1191093C (zh) 2005-03-02
AU6488099A (en) 2000-05-22
CA2348931A1 (en) 2000-05-11
US20040192644A1 (en) 2004-09-30
WO2000025825A1 (en) 2000-05-11
CN1332640A (zh) 2002-01-23
EP1155702A4 (en) 2004-12-15
IL142842A0 (en) 2002-03-10
HK1042438A1 (zh) 2002-08-16
MXPA01004239A (es) 2002-06-04
EP1155702A1 (en) 2001-11-21
TWI232930B (en) 2005-05-21
US7041818B2 (en) 2006-05-09
EA200100485A1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
ID29943A (id) Senyawa dds dan metode pengukurannya
ID29591A (id) Senyawa-senyawa kuinolina dan kuinoksalina
ID22957A (id) Senyawa dan penggunaannya
ID23575A (id) Pirazolopirimidina-pirazolopirimidina dan pirazolotriazina-pirazolotriazina
FI990466A0 (fi) Aktivaattorit ja laite
ID19422A (id) Piridina dan bifenil tersubstitusi
ID27145A (id) Metode untuk memproduksi polioksialkilena poliol dan turunan-turunannya
EE200000622A (et) Saatja-vastuvõtja GMSK ja offset-QAM jaoks
ID24148A (id) Turunan-turunan fitostfrol dan/atau fitostanol
DE69806914D1 (de) Agentimplementierte verriegelungsvorrichtung
ID22708A (id) Perangkai gen dan metodanya
ID24623A (id) Peralatan dan metode pengisian serbuk
ID22009A (id) Metoda dan peralatan destilasi
DE59810721D1 (de) Messfühler
FI981133A0 (fi) Mittausmenetelmä ja -järjestelmä
ID24196A (id) Komposisi dan penggunaan
ID16570A (id) Pembuatan amina-amina dan aminonitril-aminonitril
ID22956A (id) Sintesa disulfida dan polisulfida organik
ID24262A (id) Sensor percepatan dan peralatan percepatan menggunakan sensor percepatan
ID29053A (id) Metode untuk menghasilkan 3-alkanoilindola dan 3-alkilindola
ID26156A (id) Benzotiadiazol dan turunan-turunan
ID16889A (id) Senyawa turunan alkilaminobenzotiazol dan benzoksazol
ID18456A (id) Produksi-bersama 6-aminokapronitril dan heksametilenadiamina
ID24017A (id) Metode pembersihan pengemas dan aparatnya
ID23258A (id) Penarik pemberian-menyilang dan metodenya